Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 162

Sort by

Sort Order Select

Journal Articles

Polygenic Risk Score and Risk of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and MBL Subtypes

Geffen Kleinstern, PhD, J. Brice Weinberg, MD, Sameer A. Parikh, MD, Esteban Braggio, PhD, Dennis P. Robinson, Aaron D. Norman, MPH, Kari G Rabe, Celine M. Vachon, PhD, Connie E. Lesnick, Timothy G. Call, MD, Danielle M. Brander, MD, Janet E. Olson, PhD, James R. Cerhan, MD PhD, Neil E. Kay, MD, Curtis A. Hanson, MD, Richard R. Furman, MD, Tait Shanafelt, MD, Susan L. Slager, PhD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-136548

Published: 2020

Journal Articles

Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Chronic Lymphocytic Leukemia Who Are 80 Years of Age or Older

Paul J. Hampel, MD, Timothy G. Call, MD, Kari G Rabe, Sara J. Achenbach, Eli Muchtar, MD, Saad S. Kenderian, MB, ChB, Yucai Wang, MDPhD, Amber B. Koehler, PA-C, MS, Jose F. Leis, MD PhD, Susan M. Schwager, Daniel L. Van Dyke, PhD, Min Shi, MDPhD, Curtis A. Hanson, MD, Tait Shanafelt, MD, Esteban Braggio, PhD, Susan L. Slager, PhD, Neil E. Kay, MD, Wei Ding, MD PhD, Sameer A. Parikh, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-137578

Published: 2020

Journal Articles

Impact of Deletion6q23 Identified By FISH in Patients with Chronic Lymphocytic Leukemia

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-139068

Published: 2020

Journal Articles

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

Mitchell Smith, MD PhD, Opeyemi Jegede, PhD, Samir Parekh, MD, Curtis A. Hanson, MD, Peter Martin, FRCPC, MD MS, Brian G. Till, MD, Michael Crump, MD FRCPC, John P. Leonard, MD, Jonathan W. Friedberg, MD, Brad S. Kahl, MD, Thomas E. Witzig, MD

Blood (2019) 134 (Supplement_1): 751.

https://doi.org/10.1182/blood-2019-129323

Published: 2019

Journal Articles

Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial

Blood (2019) 134 (Supplement_1): 33.

https://doi.org/10.1182/blood-2019-126824

Published: 2019

Journal Articles

The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis

William J Archibald, MDCPA, Timothy G. Call, MD, Sara J. Achenbach, Kari G Rabe, Curtis A. Hanson, MD, Wei Ding, MD PhD, Amber Koehler, PA-C, MS, Eli Muchtar, MD, Suzanne R. Hayman, MD, Saad S. Kenderian, MD, Jose F. Leis, MD PhD, Yucai Wang, MD PhD, Amie Fonder, PA-C, MS, Min Shi, MD PhD, Daniel L. Van Dyke, PhD, Susan M. Schwager, Susan L. Slager, PhD, Neil E. Kay, MD, Sameer A. Parikh, MD

Blood (2019) 134 (Supplement_1): 3037.

https://doi.org/10.1182/blood-2019-131154

Published: 2019

Journal Articles

A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Blood (2019) 134 (Supplement_1): 4306.

https://doi.org/10.1182/blood-2019-123824

Published: 2019

Journal Articles

Myeloproliferative Neoplasms in Young Patients: The Mayo Clinic Experience with 361 Cases Age 40 Years or Younger

Natasha Szuber, MD, Mythri Mudireddy, MBBS, Maura Nicolosi, MD, Domenico Penna, MD, Rangit Reddy Vallapureddy, MBBS, Terra L. Lasho, PhD, Christy Finke, BS, Curtis A. Hanson, MD, Rhett P. Ketterling, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 3033.

https://doi.org/10.1182/blood-2018-99-117540

Published: 2018

Journal Articles

Serum Erythropoietin Levels in Essential Thrombocythemia: Phenotypic and Prognostic Correlates

Natasha Szuber, MD, Sravanthi Lavu, MBBS, Mythri Mudireddy, MBBS, Maura Nicolosi, MD, Domenico Penna, MD, Rangit Vallapureddy, MBBS, Terra L. Lasho, PhD, Christy Finke, BS, Curtis A. Hanson, MD, Rhett P. Ketterling, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 3034.

https://doi.org/10.1182/blood-2018-99-109721

Published: 2018

Journal Articles

3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups

Natasha Szuber, MD, Mythri Mudireddy, MBBS, Maura Nicolosi, MD, Domenico Penna, MD, Rangit Vallapureddy, MBBS, Terra L. Lasho, PhD, Christy Finke, BS, Kebede H. Begna, MD, Michelle A. Elliott, MD, C. Christopher Hook, MD, Alexandra Wolanskyj, MD, Mrinal M. Patnaik, MD MBBS, Curtis A. Hanson, MD, Rhett P. Ketterling, Shireen Sirhan, MD, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS, Lambert Busque, MD, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 3035.

https://doi.org/10.1182/blood-2018-99-109740

Published: 2018

Journal Articles

MPL -Mutated Essential Thrombocythemia: A Morphologic Reappraisal

Natasha Szuber, MD, Curtis A. Hanson, MD, Terra L. Lasho, PhD, Christy Finke, BS, Rhett P. Ketterling, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 3036.

https://doi.org/10.1182/blood-2018-99-115272

Published: 2018

Journal Articles

Cytogenetic Abnormalities in Systemic Mastocytosis: Who Subcategory-Specific Incidence and Prognostic Impact Among 348 Informative Cases

Sahrish Shah, MD, Animesh Pardanani, MBBS, PhD, Yoseph Elala, MD, Terra L. Lasho, PhD, Mrinal M. Patnaik, MD MBBS, Kaaren K. Reichard, MD, Curtis A. Hanson, MD, Rhett P. Ketterling, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 3050.

https://doi.org/10.1182/blood-2018-99-112628

Published: 2018

Journal Articles

Mutations and Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Mayo-Careggi Alliance Study

Paola Guglielmelli, MD PhD, Naseema Gangat, MBBS, Giacomo Coltro, MD, Terra L. Lasho, PhD, Giuseppe Gaetano Loscocco, MD, Christy Finke, BS, Benedetta Sordi, MD, Mythri Mudireddy, MBBS, Giada Rotunno, PhD, Natasha Szuber, MD, Annalisa Pacilli, PhD, Rangit Reddy Vallapureddy, MBBS, Maura Nicolosi, MD, Domenico Penna, MD, Curtis A. Hanson, MD, Rhett P. Ketterling, Animesh Pardanani, MBBS, PhD, Alessandro M. Vannucchi, MD, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 3040.

https://doi.org/10.1182/blood-2018-99-110045

Published: 2018

Journal Articles

Risk Factors for Leukemic Transformation Among 1,306 Patients with Primary Myelofibrosis: Mutations Predict Early Events

Rangit Reddy Vallapureddy, MBBS, Mythri Mudireddy, MBBS, Natasha Szuber, MD, Domenico Penna, MD, Maura Nicolosi, MD, Terra L. Lasho, PhD, Christy Finke, BS, Curtis A. Hanson, MD, Rhett P. Ketterling, Kebede H. Begna, MD, Naseema Gangat, MBBS, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 3044.

https://doi.org/10.1182/blood-2018-99-109895

Published: 2018

Journal Articles

The Germline JAK2 GGCC (46/1) Haplotype and Survival Among 414 Molecularly-Annotated Patients with Primary Myelofibrosis

Ayalew Tefferi, MD, Terra L. Lasho, PhD, Christy Finke, BS, Mythri Mudireddy, MBBS, Natasha Szuber, MD, Rangit Reddy Vallapureddy, MBBS, Domenico Penna, MD, Curtis A. Hanson, MD, Rhett P. Ketterling, Naseema Gangat, MBBS, Animesh Pardanani, MBBS, PhD

Blood (2018) 132 (Supplement 1): 1761.

https://doi.org/10.1182/blood-2018-99-110046

Published: 2018

Journal Articles

Decreased Survival and Increased Rate of Fibrotic Progression in Essential Thrombocythemia Chronicled after the FDA Approval Date of Anagrelide

Ayalew Tefferi, MD, Natasha Szuber, MD, Kebede H. Begna, MD, Mrinal M. Patnaik, MD MBBS, Michelle A. Elliott, MD, C. Christopher Hook, MD, Alexandra Wolanskyj, MD, Curtis A. Hanson, MD, Rhett P. Ketterling, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS

Blood (2018) 132 (Supplement 1): 4287.

https://doi.org/10.1182/blood-2018-99-116601

Published: 2018

Journal Articles

Cytogenetic Clonal Evolution in Myeloproliferative Neoplasms: Contexts and Prognostic Impact Among 650 Patients with Serial Bone Marrow Biopsies

Maura Nicolosi, MD, Domenico Penna, MD, Mythri Mudireddy, MBBS, Natasha Szuber, MD, Rangit Vallapureddy, MBBS, Terra L. Lasho, PhD, Christy Finke, BS, Curtis A. Hanson, MD, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS, Rhett P. Ketterling, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 4291.

https://doi.org/10.1182/blood-2018-99-109714

Published: 2018

Journal Articles

Predictors of Spleen and Anemia Response to Specific Drugs in Primary Myelofibrosis

Domenico Penna, MD, Natasha Szuber, MD, Terra L. Lasho, PhD, Christy Finke, BS, Rangit Reddy Vallapureddy, MBBS, Curtis A. Hanson, MD, Rhett P. Ketterling, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 4300.

https://doi.org/10.1182/blood-2018-99-119910

Published: 2018

Journal Articles

20+ Years and Alive with Primary Myelofibrosis: Phenotypic Signature of Very Long-Lived Patients

Domenico Penna, MD, Maura Nicolosi, MD, Mythri Mudireddy, MBBS, Natasha Szuber, MD, Rangit Vallapureddy, MBBS, Terra L. Lasho, PhD, Christy Finke, BS, Curtis A. Hanson, MD, Rhett P. Ketterling, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 4301.

https://doi.org/10.1182/blood-2018-99-109718

Published: 2018

Journal Articles

Extramedullary Hematopoiesis in the Absence of Myeloproliferative Neoplasm: Mayo Clinic Case Series of 309 Patients

Ni Fan, MD PhD, Sravanthi Lavu, MBBS, Curtis A. Hanson, MD, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 5457.

https://doi.org/10.1182/blood-2018-99-112587

Published: 2018

NARROW

Polygenic Risk Score and Risk of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and MBL Subtypes

Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Chronic Lymphocytic Leukemia Who Are 80 Years of Age or Older

Impact of Deletion6q23 Identified By FISH in Patients with Chronic Lymphocytic Leukemia

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial

The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis

A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Myeloproliferative Neoplasms in Young Patients: The Mayo Clinic Experience with 361 Cases Age 40 Years or Younger

Serum Erythropoietin Levels in Essential Thrombocythemia: Phenotypic and Prognostic Correlates

3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups

MPL -Mutated Essential Thrombocythemia: A Morphologic Reappraisal

Cytogenetic Abnormalities in Systemic Mastocytosis: Who Subcategory-Specific Incidence and Prognostic Impact Among 348 Informative Cases

Mutations and Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Mayo-Careggi Alliance Study

Risk Factors for Leukemic Transformation Among 1,306 Patients with Primary Myelofibrosis: Mutations Predict Early Events

The Germline JAK2 GGCC (46/1) Haplotype and Survival Among 414 Molecularly-Annotated Patients with Primary Myelofibrosis

Decreased Survival and Increased Rate of Fibrotic Progression in Essential Thrombocythemia Chronicled after the FDA Approval Date of Anagrelide

Cytogenetic Clonal Evolution in Myeloproliferative Neoplasms: Contexts and Prognostic Impact Among 650 Patients with Serial Bone Marrow Biopsies

Predictors of Spleen and Anemia Response to Specific Drugs in Primary Myelofibrosis

20+ Years and Alive with Primary Myelofibrosis: Phenotypic Signature of Very Long-Lived Patients

Extramedullary Hematopoiesis in the Absence of Myeloproliferative Neoplasm: Mayo Clinic Case Series of 309 Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only